转移性去势抵抗性前列腺癌患者总生存预测:通过开放临床试验数据的众包挑战开发预后模型
最佳模型为基于惩罚Cox回归集成的ePCR模型,在独立验证集ENTHUSE 33中iAUC为0·791,优于参考模型(iAUC 0·743),并在ENTHUSE M1队列中验证iAUC为0·768。研究识别了免疫生物标志物及肝肾功能标志物的预测交互效应,并发现天冬氨酸氨基转移酶为重要预后生物标志物。
要点
- ePCR模型在ENTHUSE 33验证集中iAUC为0·791,优于参考模型的0·743(贝叶斯因子>20)。
- ePCR模型将ENTHUSE 33患者分为高危和低危组,总生存差异显著(HR 3·32,95%CI 2·39-4·62,p<0·0001)。
- ePCR模型在ENTHUSE M1队列中验证iAUC为0·768。
核心结论
- 研究 delineated 新的预后因素,50种独立方法为未来方法开发建立基准。
- 数据共享结合众包挑战是开发晚期前列腺癌新预后模型的稳健且强大的框架。
研究设计与样本
- 开放数据、众包DREAM挑战,使用四项III期试验对照臂数据:ASCENT2(476例,多西他赛+泼尼松)、MAINSAIL(526例,多西他赛+泼尼松+安慰剂)、VENICE(598例,多西他赛+泼尼松或泼尼松龙+安慰剂)、ENTHUSE 33(470例,多西他赛+安慰剂)。
- 数据集包含超过150个临床变量,ASCENT2、MAINSAIL和VENICE作为训练数据,ENTHUSE 33作为独立验证(结局变量隐藏),进一步在ENTHUSE M1(266例,安慰剂单药)中验证。
- 方法评估采用积分时间依赖AUC(iAUC),参考模型基于8个临床变量和惩罚Cox比例风险模型。
主要发现
- 共开发50种独立方法预测总生存,最佳方法为基于惩罚Cox回归集成的ePCR模型。
- ePCR模型iAUC为0·791(贝叶斯因子>5),优于所有其他方法,并超过参考模型(iAUC 0·743;贝叶斯因子>20)。
- 在ENTHUSE 33中,ePCR模型将患者分为高危和低危组,总生存差异显著(HR 3·32,95%CI 2·39-4·62,p<0·0001);参考模型HR 2·56(95%CI 1·85-3·53,p<0·0001)。
- ePCR模型在ENTHUSE M1队列中验证iAUC为0·768。
- Meta分析确认了先前识别的预测临床变量,并揭示天冬氨酸氨基转移酶为重要但先前报告不足的预后生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease. METHODS: Data from the comparator arms of four phase 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from Project Data Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial. Datasets consisting of more than 150 clinical variables were curated centrally, including demographics, laboratory values, medical history, lesion sites, and previous treatments. Data from ASCENT2, MAINSAIL, and VENICE were released publicly to be used as training data to predict the outcome of interest-namely, overall survival. Clinical data were also released for ENTHUSE 33, but data for outcome variables (overall survival and event status) were hidden from the challenge participants so that ENTHUSE 33 could be used for independent validation. Methods were evaluated using the integrated time-dependent area under the curve (iAUC). The reference model, based on eight clinical variables and a penalised Cox proportional-hazards model, was used to compare method performance. Further validation was done using data from a fifth trial-ENTHUSE M1-in which 266 patients with metastatic castration-resistant prostate cancer were treated with placebo alone. FINDINGS: 50 independent methods were developed to predict overall survival and were evaluated through the DREAM challenge. The top performer was based on an ensemble of penalised Cox regression models (ePCR), which uniquely identified predictive interaction effects with immune biomarkers and markers of hepatic and renal function. Overall, ePCR outperformed all other methods (iAUC 0·791; Bayes factor >5) and surpassed the reference model (iAUC 0·743; Bayes factor >20). Both the ePCR model and reference models stratified patients in the ENTHUSE 33 trial into high-risk and low-risk groups with significantly different overall survival (ePCR: hazard ratio 3·32, 95% CI 2·39-4·62, p<0·0001; reference model: 2·56, 1·85-3·53, p<0·0001). The new model was validated further on the ENTHUSE M1 cohort with similarly high performance (iAUC 0·768). Meta-analysis across all methods confirmed previously identified predictive clinical variables and revealed aspartate aminotransferase as an important, albeit previously under-reported, prognostic biomarker. INTERPRETATION: Novel prognostic factors were delineated, and the assessment of 50 methods developed by independent international teams establishes a benchmark for development of methods in the future. The results of this effort show that data-sharing, when combined with a crowdsourced challenge, is a robust and powerful framework to develop new prognostic models in advanced prostate cancer. FUNDING: Sanofi US Services, Project Data Sphere.
引用
- Guinney J, Wang T, Laajala TD, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2016. PMID: 27864015. doi:10.1016/S1470-2045(16)30560-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。